Skip to main content

Home/ Nutrition/ Group items tagged aspirin

Rss Feed Group items tagged

Matti Narkia

Cox-2 inhibitor celecoxib might blunt effects of baby aspirin - theheart.org - 0 views

  •  
    "Ann Arbor, MI - New laboratory research suggests that the COX-2 inhibitor celecoxib (Celebrex, Pfizer), might impede the action of "baby" aspirin [1]. Dr Gilad Rimon (University of Michigan, Ann Arbor) and colleagues found evidence that this was the case in a dog model and say that "it will be important to determine" whether the same is true in humans. The report was published online December 1, 2009 in the Proceedings of the National Academy of Medicine. Celecoxib is the only COX-2 inhibitor to have remained on the market in the US, and doctors who recommend this painkiller often coprescribe a daily low dose of 81 mg of aspirin (known as a "baby" dose) to counteract any possible prothrombotic effects of the coxib, while minimizing potential gastrointestinal toxicity of the aspirin. Senior author of the new work, Dr William L Smith (University of Michigan, Ann Arbor), explained to heartwire that previous studies in humans have shown that celecoxib does not interfere with the effect of a standard dose of aspirin (325 mg), but any potential interaction of celecoxib with the lower dose has not been examined. Stagger dosing to avoid any potential problems First, Smith explained that he and his colleagues looked in vitro at celecoxib and found that it binds to one of two available sites on the COX-1 enzyme. "This surprised us," he commented. "It appears to interfere with the ability of some other drugs to affect COX-1, most notably aspirin." Second, in beagles, they administered the dog-equivalent of a baby dose of aspirin in humans and then gave some of the animals the equivalent of 100 mg of celecoxib twice daily in addition. "Celecoxib plus aspirin interfered with the normal effect of low-dose aspirin on platelets," he notes. Smith says this observation obviously requires confirmation in humans, but in the meantime he suggests "getting around the problem" by patients taking the low-dose aspirin at least 15 to 30 minutes before the celecoxib is taken, "because
Matti Narkia

Lipid mediators: lipoxin and aspirin-triggered 15-epi-lipoxins. - Bentham Science Publi... - 0 views

  •  
    Lipid mediators: lipoxin and aspirin-triggered 15-epi-lipoxins. Romano M. Inflamm Allergy Drug Targets. 2006 Apr;5(2):81-90. Review. PMID: 16613567
Matti Narkia

Aspirin-triggered lipoxin A4 blocks reactive oxygen species generation in end... - 0 views

  •  
    Aspirin-triggered lipoxin A4 blocks reactive oxygen species generation in endothelial cells: a novel antioxidative mechanism. Nascimento-Silva V, Arruda MA, Barja-Fidalgo C, Fierro IM. Thromb Haemost. 2007 Jan;97(1):88-98. PMID: 17200775 DOI: 10.1160/TH06-06-0315
Matti Narkia

Native and aspirin-triggered lipoxins control innate immunity by inducing proteasomal d... - 0 views

  •  
    Native and aspirin-triggered lipoxins control innate immunity by inducing proteasomal degradation of TRAF6. Machado FS, Esper L, Dias A, Madan R, Gu Y, Hildeman D, Serhan CN, Karp CL, Aliberti J. J Exp Med. 2008 May 12;205(5):1077-86. Epub 2008 Apr 14. PMID: 18411340 doi:10.1084/jem.20072416
Matti Narkia

15-epi-lipoxin A4-mediated induction of nitric oxide explains how aspirin inhibits acut... - 0 views

  •  
    15-epi-lipoxin A4-mediated induction of nitric oxide explains how aspirin inhibits acute inflammation. Paul-Clark MJ, Van Cao T, Moradi-Bidhendi N, Cooper D, Gilroy DW. J Exp Med. 2004 Jul 5;200(1):69-78. PMID: 15238606
Matti Narkia

The contributions of aspirin and microbial oxygenase to the biosynthesis of anti-inflam... - 0 views

  •  
    The contributions of aspirin and microbial oxygenase to the biosynthesis of anti-inflammatory resolvins: novel oxygenase products from omega-3 polyunsaturated fatty acids. Arita M, Clish CB, Serhan CN. Biochem Biophys Res Commun. 2005 Dec 9;338(1):149-57. Epub 2005 Aug 10. Review. PMID: 16112645 doi:10.1016/j.bbrc.2005.07.181    
Matti Narkia

Anti-cancer benefits of fruit and veg are underlined - The Independent 27th March 2009 - 0 views

  •  
    A diet high in fruit and vegetables, especially organically grown ones, may protect against cancer and heart disease and could be equivalent in this respect to taking a low dose of aspirin every day, scientists say.\n\nFruit and vegetables are known to have high levels of salicylates, which are also the active anti-inflammatory ingredient of aspirin. Vegetarians meanwhile are known to have low rates of cancer, as well as having higher levels of salicylates in their bodies.
Matti Narkia

Aspirin triggers antiinflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a rando... - 0 views

  •  
    Aspirin triggers antiinflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a randomized human trial. Chiang N, Bermudez EA, Ridker PM, Hurwitz S, Serhan CN. Proc Natl Acad Sci U S A. 2004 Oct 19;101(42):15178-83. Epub 2004 Oct 7. PMID: 15471991 doi: 10.1073/pnas.0405445101
Matti Narkia

Lipoxin A4 levels in asthma: relation with disease severity and aspirin sensitivity. - ... - 0 views

  •  
    Lipoxin A4 levels in asthma: relation with disease severity and aspirin sensitivity. Celik GE, Erkekol FO, Misirligil Z, Melli M. Clin Exp Allergy. 2007 Oct;37(10):1494-501. PMID: 17883729 DOI: 10.1111/j.1365-2222.2007.02806.x
Matti Narkia

Anti-inflammatory actions of lipoxin A4 and aspirin-triggered lipoxin are SOCS-2 depend... - 0 views

  •  
    Anti-inflammatory actions of lipoxin A4 and aspirin-triggered lipoxin are SOCS-2 dependent. Machado FS, Johndrow JE, Esper L, Dias A, Bafica A, Serhan CN, Aliberti J. Nat Med. 2006 Mar;12(3):330-4. Epub 2006 Jan 15. PMID: 16415877 doi:10.1038/nm1355\n
Matti Narkia

Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and the... - 0 views

  •  
    Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their aspirin-triggered endogenous epimers: an overview of their protective roles in catabasis. Serhan CN, Gotlinger K, Hong S, Arita M. Prostaglandins Other Lipid Mediat. 2004 Apr;73(3-4):155-72. Review. PMID: 15290791
Matti Narkia

Thromboxane A2 - Wikipedia, the free encyclopedia - 0 views

  •  
    Thromboxane A2 (TXA2) is a thromboxane. It is generated from prostaglandin H2 by thromboxane-A synthase. It is also a major component of blood clots. Aspirin irreversibly inhibits platelet cyclooxygenase 1 preventing the formation of prostaglandin H2, and therefore thromboxane A2. TXA2 is very unstable in aqueous solution, since it is hydrolyzed within about 30 seconds to the biologically inactive thromboxane B2. Due to its very short half life, TXA2 primarily functions as an autocrine or paracrine mediator in the nearby tissues surrounding its site of production.
Matti Narkia

Thromboxane B2 - Wikipedia, the free encyclopedia - 0 views

  •  
    Thromboxane B2 is an inactive metabolite/product of thromboxane A2. It is almost completely cleared in the urine. It itself is not involved in platelet activation and aggregation in case of a wound, but its precursor, thromboxane A2, is. Thromboxane A2 synthesis is the target of the drug aspirin, which inhibits the COX-1 enzyme (the source of thromboxane A2 in platelets).
Matti Narkia

Targeting lipoxygenases with care. - ScienceDirect - Chemistry & Biology 2006 Nov - 0 views

  •  
    Targeting lipoxygenases with care. de Souza PM, Newson J, Gilroy DW. Chem Biol. 2006 Nov;13(11):1121-2. PMID: 17113992 doi:10.1016/j.chembiol.2006.11.002  
Matti Narkia

Omega-3 fatty acids, pro-inflammatory signaling and neuroprotection. - Curr Opin Clin N... - 0 views

  •  
    Omega-3 fatty acids, pro-inflammatory signaling and neuroprotection. Bazan NG. Curr Opin Clin Nutr Metab Care. 2007 Mar;10(2):136-41. Review. PMID: 17285000
Matti Narkia

Endogenous pro-resolving and anti-inflammatory lipid mediators: a new pharmacologic gen... - 0 views

  •  
    Endogenous pro-resolving and anti-inflammatory lipid mediators: a new pharmacologic genus. Serhan CN, Chiang N. Br J Pharmacol. 2008 Mar;153 Suppl 1:S200-15. Epub 2007 Oct 29. Review. PMID: 17965751 DOI: 10.1038/sj.bjp.0707489
Matti Narkia

Novel omega -- 3-derived local mediators in anti-inflammation and resolution. - Science... - 0 views

  •  
    Novel omega -- 3-derived local mediators in anti-inflammation and resolution. Serhan CN. Pharmacol Ther. 2005 Jan;105(1):7-21. Review. PMID: 15626453 doi:10.1016/j.pharmthera.2004.09.002
Matti Narkia

RvE1 protects from local inflammation and osteoclast-mediated bone destruction in perio... - 0 views

  •  
    RvE1 protects from local inflammation and osteoclast- mediated bone destruction in periodontitis. Hasturk H, Kantarci A, Ohira T, Arita M, Ebrahimi N, Chiang N, Petasis NA, Levy BD, Serhan CN, Van Dyke TE. FASEB J. 2006 Feb;20(2):401-3. Epub 2005 Dec 22. PMID: 16373400 doi:10.1096/fj.05-4724fje
Matti Narkia

Lipoxin A4: anti-inflammatory and anti-angiogenic impact on endothelial cells. - J Immu... - 0 views

  •  
    Lipoxin A4: anti-inflammatory and anti-angiogenic impact on endothelial cells. Baker N, O'Meara SJ, Scannell M, Maderna P, Godson C. J Immunol. 2009 Mar 15;182(6):3819-26. PMID: 19265161 doi:10.4049/jimmunol.0803175
1 - 20 of 22 Next ›
Showing 20 items per page